EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
For the six months, sales was SEK 115.82 million compared to SEK 119.39 million a year ago. Net income was SEK 11.51 million compared to SEK 14.85 million a year ago. Basic earnings per share from continuing operations was SEK 0.4 compared to SEK 0.51 a year ago. Diluted earnings per share from continuing operations was SEK 0.39 compared to SEK 0.5 a year ago.